HRP20100616T1 - Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa - Google Patents

Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa Download PDF

Info

Publication number
HRP20100616T1
HRP20100616T1 HR20100616T HRP20100616T HRP20100616T1 HR P20100616 T1 HRP20100616 T1 HR P20100616T1 HR 20100616 T HR20100616 T HR 20100616T HR P20100616 T HRP20100616 T HR P20100616T HR P20100616 T1 HRP20100616 T1 HR P20100616T1
Authority
HR
Croatia
Prior art keywords
disorder
compound according
agoraphobia
receptor complex
depression
Prior art date
Application number
HR20100616T
Other languages
English (en)
Croatian (hr)
Inventor
S. Larsen Janus
Teuber Lene
K. Ahring Philip
�stergaard Nielsen Elsebet
Mirza Naheed
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of HRP20100616T1 publication Critical patent/HRP20100616T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20100616T 2006-03-24 2007-03-22 Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa HRP20100616T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78527806P 2006-03-24 2006-03-24
DKPA200600426 2006-03-24
DKPA200601327 2006-10-12
US85128406P 2006-10-13 2006-10-13
PCT/EP2007/052766 WO2007110374A1 (en) 2006-03-24 2007-03-22 Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
HRP20100616T1 true HRP20100616T1 (hr) 2011-02-28

Family

ID=39456294

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100616T HRP20100616T1 (hr) 2006-03-24 2007-03-22 Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa

Country Status (26)

Country Link
US (2) US7902230B2 (enExample)
EP (2) EP2319837B1 (enExample)
JP (1) JP5260489B2 (enExample)
KR (1) KR20080111097A (enExample)
CN (1) CN101384559B (enExample)
AR (1) AR060084A1 (enExample)
AT (1) ATE486856T1 (enExample)
AU (1) AU2007229502B2 (enExample)
BR (1) BRPI0710203A2 (enExample)
CA (1) CA2647252A1 (enExample)
CY (1) CY1111603T1 (enExample)
DE (1) DE602007010261D1 (enExample)
DK (1) DK2001855T3 (enExample)
ES (1) ES2355163T3 (enExample)
HR (1) HRP20100616T1 (enExample)
IL (1) IL192297A (enExample)
MX (1) MX2008010885A (enExample)
MY (1) MY149855A (enExample)
NO (1) NO20084481L (enExample)
NZ (1) NZ569438A (enExample)
PL (1) PL2001855T3 (enExample)
PT (1) PT2001855E (enExample)
RU (1) RU2435759C2 (enExample)
SI (1) SI2001855T1 (enExample)
TW (1) TWI391381B (enExample)
WO (1) WO2007110374A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604516A1 (en) 2005-04-13 2006-10-19 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US7923464B2 (en) 2005-12-05 2011-04-12 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
AU2008345696A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
WO2010055129A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029987A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055130A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055133A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
TW201029989A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2014053409A1 (en) * 2012-10-01 2014-04-10 F. Hoffmann-La Roche Ag Benzimidazol.es as cns active agents
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
US12139508B2 (en) * 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
KR102219563B1 (ko) * 2019-02-15 2021-02-24 에스티팜 주식회사 페나진 유도체 제조를 위한 중간체 및 그의 제조방법
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
CN116693555B (zh) * 2022-02-25 2025-07-04 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
AU2024411621A1 (en) 2023-12-27 2026-06-18 Saniona A/S A gabaa receptor ligand and the use thereof in medicine, in particular in the treatment of epilepsy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
ES2150671T3 (es) * 1995-04-21 2000-12-01 Neurosearch As Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
CA2218493C (en) * 1995-04-21 2005-02-22 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gabaa receptor complex
AU726447B2 (en) * 1996-10-21 2000-11-09 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
CN1275127A (zh) 1997-10-10 2000-11-29 神经研究公司 苯并咪唑化合物、含该化合物的药物组合物及其应用
BR0011823A (pt) * 1999-06-22 2002-03-19 Neurosearch As Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
US7335777B2 (en) 2003-04-03 2008-02-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
MXPA05010449A (es) * 2003-04-03 2006-05-31 Neurosearch As Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa.
CA2589770A1 (en) * 2004-12-01 2006-06-08 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
WO2006069381A2 (en) 2004-12-22 2006-06-29 Enterprise Integration Group Turn-taking confidence
CA2604516A1 (en) 2005-04-13 2006-10-19 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US7923464B2 (en) 2005-12-05 2011-04-12 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof

Also Published As

Publication number Publication date
CN101384559B (zh) 2012-03-14
NZ569438A (en) 2011-05-27
ATE486856T1 (de) 2010-11-15
EP2001855B1 (en) 2010-11-03
DK2001855T3 (da) 2011-02-07
WO2007110374A1 (en) 2007-10-04
PL2001855T3 (pl) 2011-04-29
MX2008010885A (es) 2008-09-08
CN101384559A (zh) 2009-03-11
US8288418B2 (en) 2012-10-16
KR20080111097A (ko) 2008-12-22
HK1132257A1 (en) 2010-02-19
IL192297A (en) 2013-11-28
JP5260489B2 (ja) 2013-08-14
DE602007010261D1 (de) 2010-12-16
PT2001855E (pt) 2011-01-17
EP2319837A1 (en) 2011-05-11
RU2008129868A (ru) 2010-04-27
CA2647252A1 (en) 2007-10-04
EP2001855A1 (en) 2008-12-17
AU2007229502A1 (en) 2007-10-04
US20090036476A1 (en) 2009-02-05
AU2007229502B2 (en) 2012-09-20
JP2009530353A (ja) 2009-08-27
BRPI0710203A2 (pt) 2011-05-24
TW200811113A (en) 2008-03-01
SI2001855T1 (sl) 2011-03-31
US20110118259A1 (en) 2011-05-19
ES2355163T3 (es) 2011-03-23
CY1111603T1 (el) 2015-10-07
NO20084481L (no) 2008-12-18
RU2435759C2 (ru) 2011-12-10
IL192297A0 (en) 2009-09-22
MY149855A (en) 2013-10-31
TWI391381B (zh) 2013-04-01
AR060084A1 (es) 2008-05-21
EP2319837B1 (en) 2012-10-31
US7902230B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
ECSP22034515A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
WO2013153479A3 (en) Indole and indazole compounds that activate ampk
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112013029149A2 (pt) processo de produção de material inorgânico em partículas